The Potential Role of Naltrexone in Borderline Personality Disorder

Azadeh Moghaddas¹, Mehrnoush Dianatkhah², Saba Ghaffari³, Padideh Ghaeli⁴*

Abstract

Objective: Management of borderline personality disorder (BPD) is a difficult challenge due to the complex features of this disorder. This article reviews the use of naltrexone in the treatment of BPD.

Method: Published articles and clinical trials were searched in Google Scholar, MedLine, ELSEVIER, and Cochrane database of systematic reviews abstracts in English language between 1990 and 2017.

Results: Naltrexone (NTX), a nonspecific competitive opiate antagonist, has been noted to be helpful in controlling self-injurious behavior (SIB) and dissociative symptoms in patients with BPD.

Conclusion: Further studies should be conducted on the effects of naltrexone to confirm the role of this medication in the treatment of BPD.

Key words: Borderline Personality Disorder, Naltrexone, Self-Injurious Behavior, Dissociative Symptoms, Psychiatry and Psychology Category

Borderline Personality Disorder (BPD) is a cluster-B personality disorder that is characterized by marked impulsivity as well as instability in affect regulation, interpersonal relationships, and self-image (1). In a recent epidemiologic survey conducted in the US, the lifetime prevalence of BPD was estimated to be about 5.9% (2). Mood changes and impulsivity are common symptoms observed in both BPD and bipolar disorders. Patients with BPD usually are full of anger and have violent outbursts. Recurring mood changes, usually lasting less than a few hours, repeated suicidal behavior, threats, or gestures, or self-mutilating acts (such as burning or cutting) are listed under BPD criteria in DSM-5. The risk for attempting suicide in the future has been reported to be increased in patients with BPD (3).

Managing BPD is challenging and is focused on treating the BPD symptoms. Standard management of BPD consists of psychotherapy as the backbone of the treatment and pharmacotherapy as an adjunct strategy (5). Medications such as serotonin reuptake inhibitors (SSRIs), antipsychotics, mood stabilizers, and anxiolytics are reported to be helpful in the treatment of BPD symptoms.

Endogenous Opioid System
The underlying neurobiological mechanism of BPD remains unclear. Alternation in the sensitivity of opioid receptors or the availability of endogenous opiates has been among the proposed neurobiological mechanisms of this disorder. Prossin et al. has measured the availability of Mu-opioid receptor in vivo by radiotracer during sustained sadness of female patients with BPD.

1. Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
2. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
3. Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
4. Psychiatry and Psychology Research Center, Roozbeh Hospital and Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

*Corresponding Author:
Address: Roozbeh Hospital, South Kargar Avenue, 1333715914, Tehran, Iran.
Tel/Fax: +98-21-66954709, E-mail:mmppg@yahoo.com

Article Information:
Received: 2016/11/07, Revised: 2017/01/17, Accepted: 2017/02/25
The distribution of involved Mu-opioid receptor exists in regions linked to emotional processing, decision-making, and pain and neuroendocrine regulating (4). The negative effects of opioid receptor agonists on BPD complications have also been noted in the literature. For example, in a case report by Thürauf et al. (2000), it was cited that consumption of potent analgesics in BPD may increase SIB that may result in severe and life-threatening injuries (6). The endogenous opioid system has been suggested to be responsible for certain clinical features such as stress related analgesia, dissociative behavior, and self-mutilating activity associated with BPD (7). Patients with BPD may unconsciously attempt to stimulate endogenous opioid and the dopaminergic reward systems by acting self-destructively like consuming substances that target opioid receptors without considerations of the consequences (8).

The exact mechanism of endogenous opioid system is not clear, but the role is evitable. One theory suggests that there are functional disturbances in the endogenous opioid system in BPD patients. Due to the disturbances and excessive basal activity in this system, self-injury commitment is not painful for BPD patients. Another theory named “addiction hypothesis” suggests that self-injury and stereotypic behavior may stimulate production and release of endorphins (9).

**Naltrexone**

Naltrexone (NTX) is a nonspecific competitive opiate antagonist that highly binds to the mu-receptor, followed by kappa and delta receptors, hindering the activity of opiates. Because endogenous opioids are involved in modulating the expression of opiates and alcohol’s reinforcing effects, NTX is clinically useful in the treatment of opiate and alcohol abuse (10). In 1984, Food and Drug Administration (FDA) approved NTX for the treatment of opiate dependence. However, NTX is mainly used in treating opiate dependence as a post withdrawal relapse prevention intervention (11). NTX has been noted to be effective in decreasing the reinforcing effects of exploitable substances and their consumption in opioid and alcohol dependent patients. However, this medication has also been suggested as a potential treatment option in several psychiatric disorders such as obesity, eating disorders, schizophrenia, self-mutilation, and other impulse control disorders (12).

The present study aimed at briefly reviewing the existing evidence on the effects of NTX in managing BPD by focusing on 2 prominent features of BPD: self-injurious behavior (SIB) and the dissociative symptoms. Because to date, no medication has obtained FDA approval for the treatment of BPD, medications like NTX need further investigations to find new ways to manage patients with BPD.

**Materials and Methods**

The authors considered searching published articles and clinical trials in Google Scholar, MEDLINE, ELSEVIER, and Cochrane database of systematic reviews abstracts in English language between 1990 and 2017.

**Results**

**Naltrexone and Self-Injurious Behavior in BPD Patients**

Self-injurious behavior, defined as self-directed act, represents a chronic and often treatment-refractory condition associated with a variety of psychiatric disorders. SIB seems to be a learned behavior for which underlying mechanisms such as positive and negative reinforcement, as well as self-stimulation have been proposed (13).

Interest is growing in developing effective treatments for individuals with SIB due to the frequent hospitalization of these patients. For minor acts, psychotherapeutic treatment modalities including social skills training and behavioral therapies are preferred ways of managing (14). However, for moderate or severe SIB, therapeutic modalities such as behavioral and psychopharmacologic interventions are only helpful to some extent. Different pharmacological medication classes have been studied in SIB treatment with antipsychotics being possibly used more than others (15).

Efficacious response to pharmacotherapy has been suggested to be due to influencing both dopaminergic and endogenous opioid systems. On the other hand, it has been noted that other neurotransmitter systems including serotonin and glutamate may also play a role in perpetuating SIB (16).

Furthermore, reduction of SIB symptoms might occur by blockade of the endogenous opioid system. NTX is noted to be one of the best choices for blocking endorphin release (17).

Opioid antagonists like NTX have been studied in the treatment of SIB in individuals with mental retardation and/or autism who exhibit injurious behaviors such as head banging, biting, or face slapping (18-20). A review article by Modesto-Loweet al. has noted a decrease in SIB among patients after NTX administration (12).

Self-injurious behavior is also one of the pathological characters of BPD which affects regulation and self-care (13). McGee reported the first case of NTX use in the management of BPD in 1997. This case presented a 28-year-old female with BPD, alcohol dependency, recurrent severe major depression, profound trauma, and neglect. She had a strong urge to cut herself to reduce her tension when under stress at work or in psychotherapy sessions. Fluoxetine was prescribed up to 80 mg per day. Although starting fluoxetine reduced depressed mood and suicide thoughts, no improvement in self-mutilation behavior was observed after 2 years of behavioral management and drug therapy. Addition of NTX (50 mg/day) into drug regime led to diminishing compulsive SIB and alcohol craving as well as decreasing the relapse rate (17).
There has been paucity of data about beneficial effects of NTX on SIB, however, in 2000: Thürauf et al. noted the benefits of this medication in reducing SIB symptoms in a female with BPD, who received NTX as a treatment option to control her SIB symptoms (6). Griengl et al. reported a 39-year-old Caucasian male patient suffering from recurrent severe SIB associated with dysthymia, who was successfully managed by NTX. In this case, SIB flared with episodic irritability, anger and feeling of guilt and it was performed by injection of inflammatory substances such as urine or nitric acid into skin and muscles. After several pharmacotherapeutic approaches including valproic acid, levetiracetam, sertraline, doxepin, and finally risperidone in appropriate dosages, naltrexone 50 mg/day was added to help treat self-destructive behavior. The intervention resulted in impressive cessation of SIB that remained during the 32-week follow-up (21).

Hence, activation of the endogenous opioid system and/or the serotonin system has been suggested to explain analgesia and mood elevation in self-mutilating BPD patients. Treatment with NTX decreased SIB in BPD like other conditions complicated with SIB. It seems that exogenous opioid abolished the mental improvements following self-injury, leading to an increase in SIB because an opioid antagonist like NTX may inhibit aggravation of psychopathology symptom in BPD and has beneficial effects in SIB among this group of patients (17).

**Naltrexone and Dissociative Symptoms in Patients with Borderline Personality Disorder:**

An important diagnostic criterion in BPD includes dissociative symptoms, which typically worsen under acute stress conditions (22). Dissociation symptoms include derealization, depersonalization, analgesia, and altered perceptions in several sensory modalities as well as pain sensitivity reduction (23).

These symptoms are a burden and may lead to subsequent complications such as nonsuicidal self-injuries and poor response to behavior therapies in BPD patients.

Psychotherapy has been the preferred approach for treating dissociative symptoms, but some pharmacotherapeutic options such as fluoxetine and paroxetine have been shown to reduce dissociative symptoms in some BPD (24).

Opioid receptor antagonists such as naloxone and NTX were found to have a promising anti-dissociative effects. For example, Pitman et al. in 1990 assessed the effects of using 2-4mg of naloxone per day in blocking stress-induced analgesia in patients with posttraumatic stress disorder (25). Two small uncontrolled open-label studies reported a reduction in dissociative symptoms in patients with chronic depersonalization (26) and depersonalization disorder (27), respectively.

Bohus et al. in 1999 studied the effects of NTX in patients with BPD and prominent dissociative phenomena including flashbacks in an open-label trial. They treated 2 groups of females suffering from BPD according to diagnostic criteria of DSM-IV (N = 13, with an overlap of 5 patients between the two groups), who experienced prominent dissociative phenomena including flashbacks. They received NTX 25 to 100 mg QID for at least 2 weeks. Patients were examined by a self-rated questionnaire which measured dissociation, analgesia, tonic immobility, and tension (DAISS) during 7 consecutive days before and during treatment with NTX. In addition, they assessed 9 other patients (with an overlap of 5 patients from the other group) for flashback protocol. Based on DAISS scores, results revealed a highly significant reduction of the duration and the severity of dissociative events and tonic immobility as well as a promising reduction in analgesia during NTX therapy. Most patients experienced a decrease in the mean number of flashbacks per day. The present study had some limitations; it only relied on self-reported phenomena instead of a questionnaire, specially applied for pain or tension reduction assessment, moreover, various doses were used, and most importantly the methodology of the study was based on open-label trial with no placebo for omitting the effects of hospitalization and other treatment protocol drugs. However, the authors proposed conducting a placebo-controlled double-blind study to assess the potential benefit of NTX in a more rigorous way (28). Hence, they examined the effects of naltrexone using a more rigorous design that controlled for major confounders such as spontaneous reduction of dissociation over time and placebo effects. Later, Schmahl et al.

| Medication       | Effect                                                                 |
|------------------|------------------------------------------------------------------------|
| Antipsychotics   | Affective dysregulation including inappropriate anger, impulsivity/aggression and interpersonal problems, moderate effects treating cognitive-perceptual symptoms, and small to moderate effects for global functioning |
| Mood stabilizers | Affective dysregulation including inappropriate anger, impulsivity and aggression, interpersonal problems, and global functioning |
| Antidepressants  | Negligible to small clinical effects for treating the symptoms of dysphoria in the absence of major depression |
studied the effects of NTX on dissociative symptoms reduction in BPD patients in a more disciplined design by controlling major confounders such as spontaneous reduction of dissociation over time and placebo effects. A total of 29 drug-naive BPD patients were assigned into 2 small, placebo-controlled double-blind trials that lasted for 6 weeks (23).

Discussion
The role of opioid antagonists in controlling the symptom of BPD patients such as dissociative symptoms or SIB is very unclear. There is paucity of data around NTX uses in BPD patients, but indirect evidence from other clinical presentation than BPD might demonstrate that NTX help treat self-injurious thoughts and behaviors (29). For instance, 2 small uncontrolled open-label studies (26, 27) found a reduction in dissociative symptoms in patients primarily suffering from depersonalization. Dissociative symptoms may result from a complex interplay of several neurochemical systems. It has been proposed that the effects of NTX on dissociative symptoms may fit current neurobiological models including opioid, serotonergic, and glutamatergic NMDA receptor systems (30).

On the other hand, several hypotheses have been suggested to explain the effects of NTX on SIB. Primarily, it has been declared that SIB may be positively reinforced by the release of endogenous opioids, producing a euphoric effect (31). Although opioid antagonists compete with endogenous opioids at the receptor binding sites, they would not activate them. Receptor blockage by opioid antagonists leads to withholding reinforcing consequences. Thus, it is suggested that frequent stimulation of endogenous opioids system results in physical dependence in SIB (32). Therefore, by preventing endogenous opioids from binding to their receptor sites, NTX withdraws the reinforcement to maintain SIB. Another hypothesis suggests that brain opioid activity enhancement generates excessive endogenous opioids, leading to an elevated pain threshold in some individuals (33). NTX has shown both encouraging and unfavorable effects in the management of SIB and dissociative manner (34, 35, 36). Such difference in treatment responses to NTX suggests possible involvement of variety of mechanisms for this medication (32).

Limitations
The main limitation of this brief review is the fact that a few controlled trials on the use of medications in BPD have been published. To this date, no medication has received FDA-approval for the treatment of BPD. Indeed, many medications like naltrexone are used to only improve distressing symptoms of BPD.

Conclusion
The role of NTX and other opioids antagonists in managing BPD complication is still controversial and incomplete. However, because no medication has obtained approval in the management of BPD, NTX is worth to be considered for further controlled trials based on some reports on its beneficial effects in reducing SIB in patients with BPD.

Acknowledgment
None

Conflict of Interest
A part of this study was presented at the 18th International Conference on Non-Communicable Diseases (ICNCD) in Amsterdam, Netherlands in 2016.

References
1. Angstman KB, Rasmussen NH. Personality disorders: review and clinical application in daily practice. Am fam physician 2011;84:1253-1260.
2. Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, Smith SM, Dawson DA, Pulay AJ, Pickering RP, Ruan WJ. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008;69:533-545.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association; 2013.
4. Prossin AR LT, Koepppe RA, Zubieta JK, Silk KR. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry 2010;167:925-933.
5. Dell’Osso B, Berlin H, Serati M, Altamura AC. Neuropsychobiological aspects, comorbidity patterns and dimensional models in borderline personality disorder. Neuropsychobiology 2010;61:169-179.
6. Thürauf NJ, Washeim HA. The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behaviour. Eur J Pain 2000;4:107-109.
7. Saper JR. Borderline personality, opioids, and naltroxone. Headache 2000;40:765.
8. Bandelow B, Schmahl C, Falkai P, Wedekind D. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev 2010;117:623-636.
9. Soloff PH. Pharmacological therapies in borderline personality disorder. In: Paris J (ed). Borderline personality disorder: Etiology and treatment. Washington, DC: American Psychiatric press; 1993.
10. Roy A, Roy M, Deb S, Unwin G, Roy A. Are opioid antagonists effective in reducing self-injury in adults with intellectual disability? A systematic review. J Intellect Disabil Res 2015; 59: 55-67.
11. Milne GM, Johnson MR. "Narcotic Antagonists and Analgeics." Annual Reports in Medicinal Chemistry 1976;11: 23-32.
12. Modesto-Lowe V, Van Kirk J. Clinical uses of naltrexone: A review of the evidence. Exp Clin Psychopharmacol 2002;10: 213.

13. Tate BG, Baroff GS. Aversive control of self-injurious behavior in a psychotic boy. Behav Res Ther 1966; 4: 281-287.

14. Lovasa OI, Smith T. Intensive and long-term treatments for clients with destructive behaviors. In: Thompson T & Gray D (Eds). Treatment of destructive disabilities. Newbury Park, CA: Sage; 1994.

15. Guaiti C, Schroder SR. Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis. Psychopharmacol Bull 1989; 25: 364-371.

16. Thompson T, Symons F, Delaney D, England C. Self-injurious behavior as endogenous neurochemical self-administration. Ment Retard Dev Disabil Res Rev 2001; 7: 137-148.

17. McGee MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 1997; 58: 32-33.

18. Buzan RD, Thomas M, Dubovsky SL, Treadway J. The use of opiate antagonists for recurrent self-injurious behavior. J Neuropsychiatry Clin Neurosci 1995; 7: 437-444.

19. Kars H, Broekema W, Glaudemans-van Gelderen I, Verhoeven WMA, Van Ree JM. Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol Psychiatry 1990; 27: 741-746.

20. Casner JA, Weinheimer B, Guaiti C. Naltrexone and self-injurious behavior: a retrospective population study. J Clin Psychopharmacol 1996; 16: 389-394.

21. Griengl H, Sendera A, Dantendorfer K. Naltrexone as a treatment of self-injurious behavior—a case report. Acta Psychiatr Scand 2001; 103: 234-236.

22. Stiglmayr CE, Ebner-Priemer UW, Bretz J, Behm R, Mohse M, Lammers CH, Anghelescu IG, Schmahl C, Schlott W, Kleindienst N, Bohus M. Dissociative symptoms are positively related to stress in borderline personality disorder. Acta Psychiatr Scand 2008; 117: 139-147.

23. Schmahl C, Kleindienst N, Limberger M, Ludäscher P, Mauchnik J, Deibler P, et al. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. International clinical psychopharmacology 2012; 27: 61-68.

24. Hoairbanks J, Fallon B, Lein Dllander E, Liebowitz, Decaria C. Treatment of Depersonalization with Serotonin: Reuptake Blockers. J Clin Psychopharmacol 1990;10: 200-202.

25. Pitman RK, van der Kolk BA, Orr SP, Greenberg MS. Naloxone-reversible analgesic response to combat-related stimuli in posttraumatic stress disorder: a pilot study. Arch Gen Psychiatry 1990; 47: 541-554.

26. Nuller YL, Morozova MG, Kushnir ON, Hamper N. Effect of naloxone therapy on depersonalization: A pilot study. J Psychopharmacol 2001; 15: 93-95.

27. Simeon D, Knultelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol 2005; 25: 267-270.

28. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999; 60: 598-603.

29. Kleindienst N, Bohus M, Ludäscher P, Limberger MF, Kuenkele K, Ebner-Priemer UW, et al. Motives for nonsuicidal self-injury among women with borderline personality disorder. J Nerv Ment Dis 2008; 196: 230-236.

30. Schmahl C, Bohus M. Translational research issues in dissociation. In: Vermetten E, Dorahy MJ, Spiegel D (Eds). Traumatic Dissociation. Neurobiology and Treatment. London: American Psychiatric press; 2007.

31. Aman MG. Pharmacotherapy in the developmental disabilities: New developments. J Intell Dev Disabil 1991; 17: 183-199.

32. Thompson T, Hackenberg T, Cerutti D, Baker DT, Axtell S. Opioid antagonist effects on self-injury in adults with mental retardation: Response form and location as determinants of medication effects. Am J Ment Retard 1994; 99: 85-102.

33. Herman BH. A possible role of proopiomelanocortin peptides in self-injurious behavior. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: S109-S139.

34. Crews WD, Bonaventura S, Rowe FB, Vonse D. Cessation of long-term naltrexone therapy and self-injury: A case study. Res Dev Disabil 1993; 14: 331-340.

35. Zingarelli G, Ellman G, Hom A, Wymore M, Heidorn S, Chicz-DeMet A. Clinical effects of naltrexone on autistic behavior. American journal of mental retardation: AJMR 1992; 97: 57-63.

36. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993; 32: 1283-1291.